Matthew Balk is 10% Owner at AzurRx BioPharma, Inc. (AZRX). They have made 1 open-market trade across 1 company since 2017, most recently 2017-06-30.
CIK 0001217674
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AZRX | 1,727,796 | $6.0M |
Shares reported on the most recent Form 4, priced at the 2017-07-05 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AZRX | SELL | 2017-06-30 | 2017-07-05 | $3.19 | $510K | -8.5% | +9.8% | -4.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.